Cellebrite DI (CLBT) Common Equity (2019 - 2025)

Cellebrite DI's Common Equity history runs 7 years deep, the most recent figure standing at $484.3 million for Q4 2025.

• In Q4 2025, Common Equity rose 44.13% year-over-year to $484.3 million; the TTM figure through Dec 2025 stood at $484.3 million (up 44.13% YoY), while the FY2025 annual figure was $484.3 million, up 44.13% from the prior year.
• Common Equity was $484.3 million for Q4 2025 at Cellebrite DI, up from $336.0 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $484.3 million in Q4 2025 to a low of -$130.0 million in Q3 2021.
• Historically, Common Equity has averaged $85.4 million across 5 years, with a median of $34.2 million in 2023.
• The sharpest annual moves came in 2021 and 2024: Common Equity sank 214.96% in 2021, then surged 882.17% in 2024.
• A 5-year view of Common Equity shows it stood at -$73.3 million in 2021, then jumped by 200.71% to $73.9 million in 2022, then sank by 53.68% to $34.2 million in 2023, then soared by 882.17% to $336.0 million in 2024, then soared by 44.13% to $484.3 million in 2025.
• The last three Common Equity figures came in at $484.3 million (Q4 2025), $336.0 million (Q4 2024), and -$40.2 million (Q2 2024), per Business Quant data.